Polymer Capital Management (Us) LLC Akebia Therapeutics, Inc. Transaction History
Polymer Capital Management (Us) LLC
- $846 Billion
- Q2 2025
A detailed history of Polymer Capital Management (Us) LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Polymer Capital Management (Us) LLC holds 12,198 shares of AKBA stock, worth $34,398. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,198Holding current value
$34,398% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
171Shares Held
106MCall Options Held
134KPut Options Held
262K-
Vanguard Group Inc Valley Forge, PA14.6MShares$41.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$32.8 Million0.0% of portfolio
-
State Street Corp Boston, MA8MShares$22.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$17.1 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$16.2 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $518M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...